1. Home
  2. ZVIA vs ACRS Comparison

ZVIA vs ACRS Comparison

Compare ZVIA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

HOLD

Current Price

$1.27

Market Cap

96.4M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVIA
ACRS
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.4M
311.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
ZVIA
ACRS
Price
$1.27
$3.74
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$4.93
$9.75
AVG Volume (30 Days)
591.8K
2.4M
Earning Date
05-25-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
55.88
69.01
EPS
N/A
N/A
Revenue
$161,259,000.00
$1,683,000.00
Revenue This Year
$8.33
N/A
Revenue Next Year
$6.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.01
N/A
52 Week Low
$1.11
$1.05
52 Week High
$3.66
$4.89

Technical Indicators

Market Signals
Indicator
ZVIA
ACRS
Relative Strength Index (RSI) 29.94 60.99
Support Level $1.11 $2.67
Resistance Level $2.76 $3.78
Average True Range (ATR) 0.09 0.24
MACD 0.00 0.06
Stochastic Oscillator 37.08 89.40

Price Performance

Historical Comparison
ZVIA
ACRS

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: